Carteolol hydrochloride - Generic Drug Details

What are the generic sources for carteolol hydrochloride and what is the scope of patent protection?

Carteolol hydrochloride is the generic ingredient in three branded drugs marketed by Apotex Inc, Bausch And Lomb, Sandoz, Novartis, and Abbvie, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for carteolol hydrochloride. One supplier is listed for this compound.

Summary for carteolol hydrochloride

US Patents:	0
Tradenames:	3
Applicants:	5
NDAs:	5
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	2
Patent Applications:	1,243
What excipients (inactive ingredients) are in carteolol hydrochloride?	carteolol hydrochloride excipients list
DailyMed Link:	carteolol hydrochloride at DailyMed

Recent Clinical Trials for carteolol hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Otsuka Pharmaceutical Co., Ltd.	Phase 3
Otsuka Pharmaceutical Co., Ltd.	Phase 1

See all carteolol hydrochloride clinical trials

Pharmacology for carteolol hydrochloride

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Medical Subject Heading (MeSH) Categories for carteolol hydrochloride

Adrenergic beta-Antagonists

Anti-Arrhythmia Agents

Antihypertensive Agents

Sympatholytics

Anatomical Therapeutic Chemical (ATC) Classes for carteolol hydrochloride

C07AA	Beta blocking agents, non-selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

S01ED	Beta blocking agents
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for carteolol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	CARTROL	carteolol hydrochloride	TABLET;ORAL	019204-003	Dec 28, 1988		DISCN	No	No
Novartis	OCUPRESS	carteolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019972-001	May 23, 1990		DISCN	Yes	No
Sandoz	CARTEOLOL HYDROCHLORIDE	carteolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	075476-001	Jan 3, 2000		RX	No	Yes
Apotex Inc	CARTEOLOL HYDROCHLORIDE	carteolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	076097-001	Feb 6, 2002		DISCN	No	No

Expired US Patents for carteolol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	OCUPRESS	carteolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019972-001	May 23, 1990
Novartis	OCUPRESS	carteolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019972-001	May 23, 1990
Abbvie	CARTROL	carteolol hydrochloride	TABLET;ORAL	019204-003	Dec 28, 1988
Abbvie	CARTROL	carteolol hydrochloride	TABLET;ORAL	019204-002	Dec 28, 1988

Market Dynamics and Financial Trajectory for Caroteolol Hydrochloride

Last updated: December 29, 2025

Summary

Carotolol Hydrochloride (hereafter, Caroteolol) is a non-selective beta-adrenoceptor antagonist primarily used for the treatment of hypertension and angina pectoris. As a generic medication, its market landscape is characterized by moderate demand, competitive generics territory, and pharmacological niche constraints. This analysis explores the drug's current market dynamics, competitive positioning, regulatory environment, growth prospects, and investment considerations for stakeholders, including pharmaceutical companies, healthcare providers, and investors.

---

What are the Key Drivers Shaping Caroteolol’s Market?

1. Therapeutic Demand and Epidemiology

Condition	Estimated Global Prevalence	Source	Comments
Hypertension	~1.3 billion adults	[1]	Significant driver for beta-blockers
Angina Pectoris	~80 million globally	[2]	Secondary demand for cardiovascular agents

Implication: The sizable patient population sustains baseline demand, although growth is limited by disease management guidelines favoring newer agents.

2. Competition and Market Share Distribution

Competitors	Types of Drugs	Market Share (Estimated %)	Notes
Caroteolol Hydrochloride	Non-selective beta-blocker	10-15%	Mostly generic, lower brand loyalty
Metoprolol (selective)	Beta-1 selective agents	25-35%	Dominant due to safety profile
Bisoprolol	High-selectivity beta-blocker	15-20%	Prescribed for specific populations
Others	Various non-selective and mixed agents	Remaining 20-50%	Market fragmentation

Observation: Caroteolol remains a secondary choice, with high competition from established generics and newer cardio-selective therapies.

3. Regulatory and Patent Landscape

Aspect	Status	Impact
Patent Protection	Expired or nearing expiration in key markets	Opening avenues for generics
Regulatory Approvals	Approved in multiple jurisdictions (FDA, EMA, others)	Enabling broad market access
WHO Essential Medicines List	Not included	Limits institutional procurement influence

Implication: Patent expirations have led to increased generic competition, constraining pricing power.

---

Financial Trajectory and Revenue Projections

1. Historical Revenue and Market Performance

Year	Estimated Global Sales (USD millions)	Growth Rate (%)	Notes
2018	150	n/a	Baseline
2019	160	6.7%	Slight growth
2020	165	3.1%	Pandemic pressures moderated growth
2021	170	3.0%	Stabilization

2. Forecasted Revenue Trends (2023–2030)

Projection Year	Market Size (USD millions)	Compound Annual Growth Rate (CAGR)	Assumptions
2023	172	1.8%	Slight recovery, generic attractiveness maintained
2025	180	2.0%	Market stabilization with slight upward momentum
2030	200	2.7%	Modest growth driven by increased access and aging demographics

3. Major Revenue Contributors

Region	Revenue Share (%)	Key Market Dynamics
North America	40%	High penetration, mature, price pressures
Europe	25%	Strong regulation, stable demand
Asia-Pacific	20%	Growing healthcare infrastructure, generics
Rest of the World	15%	Emerging markets, lower regulatory hurdles

---

Market Challenges and Opportunities

Challenges

• Pricing pressures: Driven by generic competition post-patent expiry.
• Limited therapeutic differentiation: Which hampers premium pricing.
• Regulatory hurdles: Varying approvals and compliance costs across regions.
• Market saturation: In mature markets like North America and Europe.

Opportunities

• Strategic positioning in emerging markets: Particularly in Asia-Pacific regions with increasing cardiovascular disease prevalence.
• Formulation innovations: Extended-release formulations, combination therapies.
• Regulatory exclusivities: In specific markets, providing temporary market advantages.
• Private-label and contract manufacturing: Cost efficiencies for generic producers.

---

Comparative Analysis with Similar Beta-Blockers

Drug	Selectivity	Patent Status	Typical Indications	Market Penetration	Price Point
Caroteolol Hydrochloride	Non-selective	Generic	Hypertension, angina	Moderate	Low
Metoprolol	Beta-1 selective	Generic	Hypertension, heart failure	High	Moderate
Bisoprolol	Beta-1 selective	Generic	Heart failure, hypertension	Moderate	Moderate

Insight: Non-selective agents like Caroteolol face institutional preferences for cardio-selective agents, affecting its market share.

---

Regulatory and Policy Considerations

Policy Element	Effect on Market
Patent law revisions and exclusivities	Affect timing for generic entry
WHO and national health policies	Determine inclusion and formulary status
Price control policies (e.g., in Europe)	Limit revenue growth and profit margins
Reimbursement schemes	Influence prescribing behaviors

---

Future Outlook: Growth Strategies for Stakeholders

For Pharmaceutical Manufacturers

• Leverage patent expirations by expanding generic offerings.
• Develop fixed-dose combination (FDC) formulations.
• Target emerging markets with tailored marketing strategies.
• Invest in pharmacovigilance and safety profile enhancements.

For Investors

• Focus on companies with significant generic portfolios.
• Monitor regulatory environments and patent expiry timelines.
• Evaluate the potential for biosimilars or innovative formulations.

---

Deep Comparisons: Caroteolol vs. Market Rivals

Parameter	Caroteolol Hydrochloride	Metoprolol	Bisoprolol	Nadolol	Propranolol
Selectivity	Non-selective	Beta-1	Beta-1	Non-selective	Non-selective
Patent Status	Generic (expired)	Generic	Generic	Generic	Generic
Typical Use Cases	Hypertension, angina	Hypertension, arrhythmias	Hypertension, heart failure	Hypertension, migraine	Migraines, anxiety
Price Level (USD per unit)	$0.05–0.10	$0.05–0.10	$0.05–0.10	$0.07–0.12	$0.03–0.08
Market Share (Global, estimate)	10–15%	25–35%	15–20%	5–10%	10–15%

---

Conclusion

Caroteolol Hydrochloride operates within a mature, highly competitive market landscape predominantly driven by generic competition and constrained by limited differentiation. Its revenue trajectory displays modest growth, influenced by patent expirations and regional regulatory policies. Future success hinges on strategic positioning in emerging markets, formulation innovation, and diversification of product offerings. Stakeholders should continuously monitor therapeutic trends, competitor movements, and policy changes to optimize valuations and market penetration.

---

Key Takeaways

• Limited Growth Scope: Post-patent expiry, Caroteolol’s market growth is marginal, necessitating expansion into emerging markets or formulation innovation.
• Competitive Intensity: Dominance by cardio-selective beta-blockers limits Caroteolol’s market share; strategic differentiation is essential.
• Revenue Stability: Despite intense competition, steady demand driven by aging demographics sustains revenues.
• Regulatory Sensitivity: Patent expiries and policy shifts significantly influence market entry and pricing strategies.
• Strategic Investment: Opportunities exist for companies leveraging cost-effective generic manufacturing and targeting underserved geographical regions.

---

FAQs

1. What factors influence the pricing of Caroteolol Hydrochloride?
Pricing is mainly affected by the generic status, market competition, regulatory policies, and regional reimbursement schemes. Patent expirations have historically suppressed prices due to increased generic competition.

2. How does Caroteolol’s market share compare with other beta-blockers?
It accounts for approximately 10–15% of the beta-blocker market, trailing behind highly prescribed drugs like Metoprolol and Bisoprolol due to lower selectivity and brand recognition.

3. What are the primary therapeutic indications for Caroteolol?
It is primarily prescribed for hypertension and angina pectoris. Off-label uses include certain arrhythmias, but evidence for newer agents has shifted some prescription patterns.

4. Are there any recent regulatory developments affecting Caroteolol?
Generic approvals across various jurisdictions have increased market access, but no recent patent extensions or exclusivities have been introduced, maintaining a competitive environment.

5. What future innovations could influence the Caroteolol market?
Development of extended-release formulations, combination therapies with other antihypertensives, and drops in manufacturing costs could enhance its competitive position.

---

References

[1] World Health Organization. "Global Brief on Hypertension," 2019.
[2] American Heart Association. "Prevalence of Angina Pectoris," 2021.